Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
The coprimary objectives of the study are to test whether ixekizumab Q2W/Q4W is superior to FAE and is superior to MTX at Week 24 in the treatment of patients with moderate-to-severe psoriasis who are candidates for systemic therapy as measured by 75% improvement in Psoriasis Area and Severity Index (PASI 75) from baseline assuming, that non-adherent patients are treatment failures.
Inclusion criteria
- Moderate to Severe Plaque Psoriasis